Asian Currencies Trade Flat as Dollar Retreats After Fed Decision 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
ECB’s Cipollone Backs Digital Euro as Europe Pushes for Payment System Independence 
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Australia Inflation Surprise Fuels Rate Hike Expectations Ahead of RBA Meeting 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
The Maire - EuroChem Case: Three Lessons for Global Business 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
UK Housing Market Gains Momentum in Early 2026 as Mortgage Rates Fall 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Australia Wine Exports Fall in 2025 as Global Drinking Declines and China Demand Weakens 
Celltrion and Mirae Asset were said to have agreed on buying the largest stake in the UK-headquartered antibody-drug conjugates developer, Iksuda Therapeutics. Based on the report, the deal between the companies is worth $47 million.
The stake acquisition deal
As per The Korea Economic Daily, with its huge investment, Celltrion Inc. is expecting to expand its cancer drug line. The biopharmaceutical company headquartered in Incheon, South Korea, wants to develop more treatments in addition to its Truxima, a blood cancer drug, and Herzuma for breast cancer.
It was said that Iksuda has four ADC-based drugs that are already in pre-clinical development, including B-cell lymphomas. Celltrion can make use of these once the deal is fully completed.
ADC is an advanced technology that was created to specifically target a cancer cell. In any case, Celltrion and Mirae Asset have paid half of the investment price to the British biotech firm, and the rest of the payment will be delivered once agreed development milestones are reached.
"This stake investment will create synergy with our antibody treatments and add next-generation anticancer drugs to our pipeline," a Celltrion official said.
The benefits from the investments for Iksuda
Celltrion and Mirae Asset’s investment in Iksuda Therapeutics will make them the largest stakeholder in the UK-based company. The funding coming from the Korean firms will go to the development and advancement of Iksuda’s lead ADC assets and other technologies.
It was mentioned that Iksuda’s lead pre-clinical drug is called IKS03, and it is said to be a “best-in-class” CD19-targeted ADC candidate for B-cell cancers. Celltrion and Mirae’s multi-million investment will be used for IKSO3 to progress from its first human phase 1 clinical trial.
“This is a transformational investment milestone for Iksuda, enabling us to focus on the progression of our industry-leading ADC programs and bring them to the clinic, whilst supporting our commercial growth,” Iksuda Therapeutics CEO, Dr.Dave Simpson, said in a press release. “The funding not only reflects the potential of our technologies but also the unmatched expertise of the Iksuda team. We are grateful for the support of this group of investors and delighted to welcome them to the team.
